Copyright
©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Jun 14, 2005; 11(22): 3346-3350
Published online Jun 14, 2005. doi: 10.3748/wjg.v11.i22.3346
Published online Jun 14, 2005. doi: 10.3748/wjg.v11.i22.3346
Table 1 Characteristics of patients with positive HBeAg at enrollment.
Group 1 (n = 10) | Group 2 (n = 8) | Group 3 (n = 9) | Group 4 (n = 10) | ||
Age in years (mean±SD) | 38.8±9.7 | 40.0±9.1 | 34.1±12.9 | 31.2±10.2 | P = 0.07 |
Gender (male/female) | 10/0 | 6/2 | 4/5 | 7/3 | P = 0.01 |
ALT (IU/L) | 695±450 | 89±45 | 325±195 | 89±38 | P = 0.01 |
HBV DNA (LGE/mL) | 7.4±1.4 | 7.5±0.9 | 7.2±1.5 | 8.2±0.5 | P = 0.06 |
Genotype (A/B/C) | 0/0/10 | 1/0/6 | 0/0/9 | 0/0/10 | P = NS |
Precore (wild/mutant) | 9/1 | 6/1 | 8/1 | 10/0 | P = NS |
Core promoter (wild/mutant) | 5/5e | 2/5 | 1/8 | 4/6 | P = 0.14 |
Fibrosis stage (F1/F2/F3) | 1/3/1 | 3/1/2 | 0/4/1 | 3/1/0 | P = 0.06 |
- Citation: Kurihara T, Imazeki F, Yokosuka O, Fukai K, Kanda T, Kawai S, Saisho H. Effect of lamivudine in HBeAg-positive chronic hepatitis B: Discordant effect on HBeAg and HBV DNA according to pretreatment ALT level. World J Gastroenterol 2005; 11(22): 3346-3350
- URL: https://www.wjgnet.com/1007-9327/full/v11/i22/3346.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i22.3346